Item 2.02 Results of Operations and Financial Condition.

On May 16, 2022, we announced our financial results for the three months ended March 31, 2022 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.

The information in this Item 2.02 and the attached Exhibit 99.1 is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 2.02 and the attached Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.

Item 7.01 Regulation FD Disclosure.

On May 16, 2022, we issued a press release announcing the entry into a definitive agreement with Emergent BioSolutions Inc. to acquire our exclusive worldwide rights to brincidofovir, including TEMBEXA. A copy of the press release is attached hereto as Exhibit 99.2 and is incorporated herein by reference.

The information in this Item 7.01 and the attached Exhibit 99.2 is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 7.01 and the attached Exhibit 99.2 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.

Item 9.01 Financial Statements and Exhibits.





(d)Exhibits

 Exhibit No.       Description
     99.1            Press Release of Chimerix, Inc. dated May 16, 2022.
     99.2            Press Release of Chimerix, Inc. dated May 16, 2022.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses